US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’

US drug maker Eli Lilly is cutting its investment in a German factory by half. This decision follows new healthcare cost-cutting laws in Germany. The company CEO called the reforms a bad signal for the industry. This move impacts Germany's industrial plans. The factory will now operate at reduced capacity with fewer jobs. Other companies are also reconsidering local investments.

By TOI TECH DESK